ReviewInternational journal of nanomedicine2026
Nanoreagents Against the Blood-Testis Barrier: A Strategy for Diagnosing and Treating Male Reproductive System Diseases.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Male reproductive health represents a critical yet challenging area of medical science, where conventional diagnostics and therapies are often limited by physiological barriers-particularly the blood-testis barrier (BTB)-and the complex etiology of disorders such as infertility, prostate cancer, and erectile dysfunction. In recent years, nanoreagents has emerged as a transformative tool, enabling unprecedented advances in drug delivery, imaging, and therapeutic precision. This review systematically examines the application of diverse nanomaterials-including metal nanoparticles, lipid-based systems, polymeric carriers, and natural derivatives such as nanobodies, extracellular vesicles, and cell membrane-coated nanoparticles-in the context of male reproductive medicine. These platforms facilitate targeted drug delivery across the BTB, enhance local drug bioavailability, minimize systemic toxicity, and support sustained release profiles. In diagnostic imaging, nanotechnology augments modalities such as MRI, PET, and photoacoustic imaging. Furthermore, natural biomaterials offer biocompatible and immunologically inert strategies for drug encapsulation and targeted transport, improving both efficacy and safety. Despite these promising developments, challenges remain in standardization, long-term biosafety, and scalable synthesis. Nevertheless, the integration of nanotechnology in male reproductive health is poised to redefine treatment paradigms, offering personalized, efficient, and minimally invasive solutions. As research progresses, nano-based approaches hold significant potential to address unmet clinical needs and improve reproductive outcomes worldwide.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.